Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Table 3 Changes of plasma HbA1c, blood lipids and cardiac function between Baseline and End of Study (week 24)

Variables	Liraglutide monotherapy	Metformin monotherapy	P	Liraglutide (1.8 mg/d) monotherapy	Liraglutide plus Metformin dual therapy	P
BMI (kg/m²)	−1.07 ± 0.23	−0.73 ± 0.14	<0.001	−1.13 ± 0.16	−1.20 ± 0.21	0.152
HbA1c (%)			0.278			0.093
%	−2.6 ± 0.3	−2.5 ± 0.4		−2.6 ± 0.4	−2.8 ± 0.5
mmol/mol	−28 ± 3	−27 ± 4		−28 ± 0.4	−31 ± 5
PPG (mmol/L)	−5.8 ± 1.7	−5.5 ± 1.6	0.484	−5.4 ± 1.5	−5.7 ± 1.6	0.459
TC (mmol/L)	−0.7 ± 0.4	−0.5 ± 0.3	0.033	−0.7 ± 0.3	−0.9 ± 0.4	0.033
LDL-C (mmol/L)	−0.6 ± 0.3	−0.4 ± 0.2	0.003	−0.5 ± 0.3	−0.8 ± 0.4	0.002
CRP (mg/L)	−4.3 ± 1.2	−2.4 ± 1.0	<0.001	−4.1 ± 0.8	−4.8 ± 1.0	0.004
SBP (mmHg)	−11 ± 4	−4 ± 2	<0.001	−11 ± 3	−12 ± 4	0.278
DBP (mmHg)	−6 ± 3	−3 ± 1	<0.001	−6 ± 3	−7 ± 4	0.278
LVEDD (mm)	−9 ± 4	−5 ± 3	<0.001	−8 ± 3	−10 ± 4	0.033
EF (%)	5 ± 3	3 ± 2	0.004	5 ± 2	7 ± 3	0.004
E/A ratio	0.16 ± 0.04	0.05 ± 0.02	<0.001	0.14 ± 0.02	0.18 ± 0.04	<0.001

Abbreviations: BMI body mass index, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LVEDD left ventricular end-diastolic diameter, EF ejection fraction

ISSN: 1476-511X